MannKind Corporation
Afrezza
type 1 or type 2 diabetes
Countdown
542days
Phase 2 readout · ~ Dec 31, 2027 estimated
What's at stake
Phase 2 trial results for Afrezza in type 1 or type 2 diabetes are due ~ Dec 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Data from this study is expected to be available in late 2027.”